SMO and chronic myelogenous leukemia, BCR-ABL1 positive: Two other clinical trials on dual TKI and SMO inhibitor treatments have also been conducted for CML with one assessing the combination of Dasatinib with BMS-933923 and the other evaluating Nilotinib with LDE225.